NCT01760343View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Hereditary Angioedema Types I and II
Interventions
BIOLOGICAL

Berinert

Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.

BIOLOGICAL

CSL830

CSL830 is a formulation of Berinert.

Trial Locations (1)

Unknown

Study Site, Berlin

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT01760343 - A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor | Biotech Hunter | Biotech Hunter